Description

Cibinetide is an 11-amino-acid peptide derived from the tissue-protective segment of erythropoietin, modified to eliminate erythropoietic stimulation while retaining anti-oxidative and anti-apoptotic properties. It has shown significant efficacy in protecting tissues like the retina, kidney, and heart from ischemic and inflammatory damage. Cibinetide modulates innate immune responses—particularly macrophage activation and cytokine release—highlighting its potential in tissue repair and inflammatory injury models.

Manufactured under GMP conditions with 99.06% purity, this peptide ensures high reliability for experimental use in cytoprotection and inflammation research.

Product Specifications

Mechanism of Action & Research Applications

Cibinetide engages a protective receptor complex, activating anti-apoptotic and anti-oxidant signaling cascades in stressed cells. It suppresses inflammatory cytokines and enhances cell survival under hypoxia or injury.

Applications include:

• Retinal protection in ischemic and diabetic injury models

• Renoprotective studies following kidney ischemia or toxin exposure

• Cardiac tissue recovery research post-ischemia

• General inflammation and oxidative stress models in cell and tissue systems

Side Effects (Research Context Only)

In laboratory and animal models, Cibinetide generally shows an excellent safety profile. Noted effects may include:

• Increased cell survival rates under stress

• Reduced expression of pro-inflammatory cytokines

• No detectable hematopoietic stimulation or red blood cell production
  These observations aid in evaluating tissue-protective strategies without erythropoietic confounders.

Disclaimer

Cibinetide is intended solely for laboratory research use. It is not approved for clinical or veterinary use. Please handle in compliance with laboratory safety protocols.